Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer
Investigators aim to investigate whether circulating tumor DNA is a sensitive marker to evaluate patients' response to neoadjuvant chemotherapy
Neoadjuvant chemotherapy(NAC) is traditionally for locally advanced disease, converting an inoperable to a resectable tumor.In recent years, it has become an option for patients of lower tumor stage to increase the possibility of breast conserving therapy. An effective method to monitor the response to NAC is important.
Inclusion Criteria:
Exclusion Criteria:
lishunying@foxmail.com+86-15915939702
Guandong, Guangdong, China
lishunying@foxmail.com+86-15915939702